72
Participants
Start Date
July 30, 2025
Primary Completion Date
July 31, 2026
Study Completion Date
July 31, 2027
TQB2922 injection ± TAS-102 tablets
TQB2922 is an anti-EGFR/c-Met bispecific antibody, subtype Immunoglobulin G1 (IgG1). TQB2922 blocks the activation of EGFR and c-Met signalling pathway by binding to EGFR and c-Met on the surface of tumour cells, thus preventing tumour growth and progression. At the same time, TQB2922 can target EGFR and c-Met on the surface of tumour cells through antibody-dependent cytotoxicity (ADCC) and antibody-dependent cell phagocytosis by natural killer cells and macrophages, thus killing tumour cells.
TQB2922 injection+TAS-102 tablets ± Bevacizumab
TQB2922 is an anti-EGFR/c-Met bispecific antibody, subtype IgG1. TQB2922 blocks the activation of EGFR and c-Met signalling pathway by binding to EGFR and c-Met on the surface of tumour cells, thus preventing tumour growth and progression. At the same time, TQB2922 can target EGFR and c-Met on the surface of tumour cells through antibody-dependent cytotoxicity (ADCC) and antibody-dependent cell phagocytosis by natural killer cells and macrophages, thus killing tumour cells.
NOT_YET_RECRUITING
National Cancer Center/Chinese Academy of Medical Sciences Cancer Hospital, Beijing
NOT_YET_RECRUITING
The First Affiliated Hospital of China Medical University, Shenyang
NOT_YET_RECRUITING
Jilin Cancer Hospital, Changchun
NOT_YET_RECRUITING
Harbin Medical University Cancer Hospital, Harbin
NOT_YET_RECRUITING
Fudan University Shanghai Cancer Center, Shanghai
NOT_YET_RECRUITING
Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai
NOT_YET_RECRUITING
Jiangsu Cancer Hospital, Nanjing
NOT_YET_RECRUITING
Jiangsu Provincial People's Hospital, Nanjing
NOT_YET_RECRUITING
Jiangnan University Affiliated Hospital, Wuxi
NOT_YET_RECRUITING
Suzhou Municipal Hospital, Suzhou
NOT_YET_RECRUITING
The First Affiliated Hospital of Anhui Medical University, Hefei
NOT_YET_RECRUITING
Shandong Public Health Clinical Center, Jinan
RECRUITING
Qingdao Municipal Hospital, Qingdao
NOT_YET_RECRUITING
Jiangxi Cancer Hospital, Nanchang
NOT_YET_RECRUITING
Zhongshan Hospital Affiliated to Xiamen University, Xiamen
NOT_YET_RECRUITING
The First Affiliated Hospital of Chongqing Medical University, Chongqing
NOT_YET_RECRUITING
Hunan Cancer Hospital, Changsha
NOT_YET_RECRUITING
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan
NOT_YET_RECRUITING
Xinyang Central Hospital, Xinyang
NOT_YET_RECRUITING
Zhoukou Central Hospital, Zhoukou
NOT_YET_RECRUITING
The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou
NOT_YET_RECRUITING
Meizhou People's Hospital, Meizhou
NOT_YET_RECRUITING
Shantou University Medical College Affiliated Cancer Hospital, Shantou
NOT_YET_RECRUITING
Guangxi Zhuang Autonomous Region Cancer Hospital, Nanning
NOT_YET_RECRUITING
Yibin First People's Hospital, Yibin
NOT_YET_RECRUITING
The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an
NOT_YET_RECRUITING
The First Hospital of Shanxi Medical University, Taiyuan
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
INDUSTRY